Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. (Q45868489)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 September 2014

Language	Label	Description	Also known as
English	Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.	scientific article published on 11 September 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Valerie Chamouard

0 references

5

object named as

Jerzy Windyga

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Jerry Powell

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Amy Shapiro

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Margaret Ragni

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Margareth Ozelo

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

John Pasi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Ross Baker

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

James Potts

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Shuanglian Li

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Baisong Mei

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Glenn F Pierce

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Brian Robinson

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

0 references

publication date

11 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

168

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

113-123

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25209873%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

The burden of bleeding in haemophilia: is one bleed too many?

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Use of clinical practice guidelines on long-term prophylaxis in severe hemophilia in France: a retrospective audit.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Prolonged activity of factor IX as a monomeric Fc fusion protein

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Guidelines for the management of hemophilia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13109

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45868489&oldid=1895426791"